Loading…
Quantum BioPharma Ltd. is projected to rise to $4.01 by 2027, a +21% move from its current price of $3.31. QNTM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $3.14 | $3.31 | $3.49 | -0.01% |
| Jul 15 | $3.07 | $3.31 | $3.57 | -0.02% |
| Jul 16 | $3.01 | $3.31 | $3.63 | -0.04% |
| Jul 17 | $2.97 | $3.31 | $3.69 | -0.05% |
| Jul 18 | $2.93 | $3.31 | $3.73 | -0.06% |
| Jul 19 | $2.90 | $3.31 | $3.78 | -0.07% |
| Jul 20 | $2.87 | $3.31 | $3.82 | -0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.87 | $3.31 | $3.82 | -0.09% |
| Week 2 | $2.70 | $3.30 | $4.05 | -0.17% |
| Week 3 | $2.58 | $3.30 | $4.23 | -0.26% |
| Week 4 | $2.48 | $3.30 | $4.39 | -0.34% |
| Week 5 | $2.39 | $3.30 | $4.54 | -0.43% |
| Week 6 | $2.32 | $3.29 | $4.68 | -0.52% |
| Week 7 | $2.25 | $3.29 | $4.81 | -0.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Quantum BioPharma Ltd. is a biopharmaceutical company that operates through two segments: Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development.
Its lead compound is Lucid-MS, a patented new chemical entity in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property.
The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada. It is categorized in Healthcare.
Quantum BioPharma Ltd. (QNTM) trades at current price $3.36 with a market capitalization of $21.5M, and it ranks 4895 by market cap. The asset operates in Healthcare and presents an overall price outlook that, in the long run, shows potential for appreciation from current levels, with the average price rising toward the mid-to-high single digits by the 2030s and well into the 2040s and 2050s in the forecast data.
According to the year-by-year forecast, the average price moves from $3.36 in 2026 to $9.97 by 2050, with maximums climbing as high as $22.92 and minimums dipping to levels around $2.10 in some years. The trajectory includes intermittent neutral and bullish periods, reflecting a gradual long-term upside tempered by shorter-term volatility.
A major floor 76.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.2% away) — a key level to hold.
The nearest ceiling, 112.1% above — a clean break opens room to run.
A major ceiling 179.2% above — clearing it would confirm fresh momentum.
Key QNTM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of QNTM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.35 | Sell | $3.37 | Sell |
| MA 10 | $3.47 | Sell | $3.48 | Sell |
| MA 20 | $3.65 | Sell | $3.78 | Sell |
| MA 50 | $4.95 | Sell | $4.32 | Sell |
| MA 100 | $4.22 | Sell | $4.99 | Sell |
| MA 200 | $6.96 | Sell | $6.86 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.97 | Neutral |
| Stoch RSI (14) | 28.43 | Neutral |
| CCI (20) | -114.78 | Sell |
| Williams %R (14) | -93.94 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -14.03 | Sell |
| Bollinger %B (20,2) | 0.13 | Neutral |
| Stochastic %K (14) | 6.06 | Buy |
| TRIX (15) | -1.50 | Sell |
| Awesome (5,34) | -1.19 | Sell |
| Ultimate (7,14,28) | 31.13 | Neutral |
| Momentum (10) | -0.62 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 3.28 | Buy |
| ADX (14) | 24.15 | Sell |
| ATR (14) | 0.20 | Info |
The 30-day technical picture is bearish, with RSI(14) at 40 and price currently trading around the nearby support. The stock remains below the short- and long-term moving averages, with the SMA50 at $5.02 and the SMA200 at $7.40, indicating a down-tilt in the near term.
Support is identified at $3.36 and resistance at $9.24, framing a 30-day range of $2.22 to $5.08. These levels help define near-term risk and potential bounce points as volatility remains high (annualized volatility of 100%). The current setup suggests a cautious stance in the immediate horizon, with potential for a move back toward the support if selling pressure persists.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.10 | $3.31 | $4.25 | 0% | Neutral | |
| $2.91 | $4.01 | $5.97 | +21% | Bullish | |
| $2.61 | $3.82 | $6.07 | +15% | Neutral | |
| $2.35 | $3.63 | $6.05 | +10% | Neutral | |
| $2.06 | $3.33 | $5.78 | +1% | Neutral | |
| $1.92 | $3.25 | $5.84 | -2% | Neutral | |
| $2.24 | $3.95 | $7.32 | +19% | Neutral | |
| $2.60 | $4.77 | $9.09 | +44% | Bullish | |
| $2.80 | $5.36 | $10.46 | +62% | Bullish | |
| $2.69 | $5.34 | $10.67 | +61% | Bullish | |
| $3.55 | $7.89 | $17.32 | +138% | Bullish | |
| $4.48 | $9.96 | $22.90 | +201% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.10 | $3.31 | $4.12 | +0.00% |
| August 2026 | $2.68 | $3.25 | $4.10 | -1.88% |
| September 2026 | $2.66 | $3.27 | $4.22 | +0.77% |
| October 2026 | $2.75 | $3.42 | $4.48 | +4.43% |
| November 2026 | $2.63 | $3.31 | $4.39 | -3.30% |
| December 2026 | $2.49 | $3.16 | $4.25 | -4.49% |
Click any year to see its month-by-month QNTM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The QNTM price prediction for 2026 points to an average of $3.31 (low $2.10, high $4.25) — a potential gain of 0% on today's $3.31. A consolidation phase looks the most probable path here.
In 2027, QNTM is projected to trade between $2.91 and $5.97, averaging $4.01 — a potential gain of +21% from today's $3.31. That is up +21% on the projected 2026 average. Momentum favours further upside here.
Quantum BioPharma Ltd.'s 2028 outlook centres on $3.82, within a $2.61 to $6.07 range. That is -5% versus the projected 2027 average. That marks a +15% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, QNTM could reach as high as $6.05, with a base case around $3.63 and support toward $2.35 — roughly +10% from $3.31. Price action looks broadly range-bound.
Expect QNTM to range from $2.06 to $5.78 through 2030. The $3.33 average target implies a +1% move from current prices. That is -8% versus the projected 2029 average. A consolidation phase looks the most probable path here.
The QNTM price prediction for 2031 points to an average of $3.25 (low $1.92, high $5.84) — a potential decline of -2% on today's $3.31. Price action looks broadly range-bound.
In 2032, QNTM is projected to trade between $2.24 and $7.32, averaging $3.95 — a potential gain of +19% from today's $3.31. That is up +22% on the projected 2031 average. A consolidation phase looks the most probable path here.
Quantum BioPharma Ltd.'s 2033 outlook centres on $4.77, within a $2.60 to $9.09 range. That is up +21% on the projected 2032 average. That marks a +44% change versus current levels. Momentum favours further upside here.
By 2034, QNTM could reach as high as $10.46, with a base case around $5.36 and support toward $2.80 — roughly +62% from $3.31. Buyers look set to stay in control over this stretch.
Expect QNTM to range from $2.69 to $10.67 through 2035. The $5.34 average target implies a +61% move from current prices. That is 0% versus the projected 2034 average. Momentum favours further upside here.
The QNTM price prediction for 2040 points to an average of $7.89 (low $3.55, high $17.32) — a potential gain of +138% on today's $3.31. Buyers look set to stay in control over this stretch.
In 2050, QNTM is projected to trade between $4.48 and $22.90, averaging $9.96 — a potential gain of +201% from today's $3.31. That is up +26% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in QNTM today (≈ 302.114804 QNTM) could be worth
$3,008.46
+$2,008.46 (+201%) by 2050 · US Dollar
Based on the average projected QNTM price of $9.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in QNTMwould be worth at today's price.
$1,000 invested in QNTM on Jul 10, 2025 (≈ 52.854122 QNTM) would be worth
$174.95
-$825.05 (-82.5%) today · 0.17× · US Dollar
Based on a QNTM entry price of $18.92 vs. today's $3.31.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.51 | $943.02 | -5.7% |
| 1 month ago | $3.93 | $842.24 | -15.8% |
| 3 months ago | $3.53 | $939.01 | -6.1% |
| 6 months ago | $6.96 | $475.57 | -52.4% |
| 1 year ago | $18.92 | $174.95 | -82.5% |
| All time (5.0y) ago | $99.45 | $33.28 | -96.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our QNTM forecast.
Our base-case forecast reaches $6.60 around 2040.
Implied market cap at $6.60: $42.23M
The multi-year forecast shows a gradual upward trajectory from 2026 through 2050. The average price rises from $3.36 in 2026 to $9.97 by 2050, with max values up to $22.92 and min values as low as $2.10 in 2026–2031. The forecast highlights a notable acceleration in price strength toward the late 2030s and into 2040 and beyond, with 2040 average $7.80 and 2050 average $9.97.
ROI figures accompany the path, starting near-zero in 2026 and climbing to 24.9% in 2027, then reaching 132% by 2040 and 196.6% by 2050. Notably, there is a negative year in 2031 with -5.8% ROI, illustrating the inherent volatility and risk embedded in long-range projections. The sentiment shifts to bullish in several later years (2033, 2034, 2035, 2040, 2050) alongside expanding price ranges, underscoring a potential but uncertain upside.
Overall, these are estimates reflecting a broad long-horizon uptrend with meaningful upside in later years, tempered by shorter-term volatility and a few negative intervals. Investors should treat these figures as projections, not guarantees, and consider the inherent risk given the small market cap and sector dynamics.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $3.42 with an estimated ROI of 1.9% (min $2.11, max $5.95).
The year-by-year forecast includes years with positive ROIs (e.g., 24.9% in 2027, 132% in 2040, 196.6% in 2050), but also a negative year (-5.8% in 2031). These are estimates, not guarantees.
Yes. The forecast shows a max of $9.26 in 2033, with higher max values of $10.33 in 2034 and $10.95 in 2035, meaning the $9.24 level is surpassed in at least one scenario (2033 max $9.26).
Current price is $3.36 and market cap is $21.5M. The company ranks 4895 by market cap.
The 30-day range is $2.22 to $5.08.
Quantum BioPharma Ltd. Community Discussion
0Share your Quantum BioPharma Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.